155 related articles for article (PubMed ID: 7872701)
1. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
Naik H; Lehr J; Akhtar A; Pienta K
Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
[TBL] [Abstract][Full Text] [Related]
2. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
Naik HR; Lehr JE; Pienta KJ
Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Naik H; Lehr JE; Pienta KJ
Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
Hatano K; Nonomura N; Nishimura K; Kawashima A; Mukai M; Nagahara A; Nakai Y; Nakayama M; Takayama H; Tsujimura A; Okuyama A
Jpn J Clin Oncol; 2011 Feb; 41(2):253-9. PubMed ID: 21071389
[TBL] [Abstract][Full Text] [Related]
7. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
[TBL] [Abstract][Full Text] [Related]
9. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
10. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo.
Nguyen NM; Lehr JE; Pienta KJ
Anticancer Res; 1993; 13(6A):2143-7. PubMed ID: 7507655
[TBL] [Abstract][Full Text] [Related]
11. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
[TBL] [Abstract][Full Text] [Related]
12. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
[TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
14. An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis.
Dandekar DS; Lokeshwar VB; Cevallos-Arellano E; Soloway MS; Lokeshwar BL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):59-66. PubMed ID: 12734674
[TBL] [Abstract][Full Text] [Related]
15. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
18. Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
Block NL; Camuzzi F; Stover B; Claflin A; Troner M; Politano VA
Trans Am Assoc Genitourin Surg; 1978; 70():57-9. PubMed ID: 753023
[TBL] [Abstract][Full Text] [Related]
19. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
[TBL] [Abstract][Full Text] [Related]
20. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]